STA
FLXN

Summit Trail Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Summit Trail Advisors’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-18
Closed – – 1879
2017
Q4 		$0 Buy
+18
New +$441 ﹤0.01% 2137

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Summit Trail Advisors's FLXN Position: Q1 2018 in Review

Summit Trail Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2018, closing a stake of 18 shares.

Summit Trail Advisors first reported a position in FLXN in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 134 funds tracked by Wall St. Rank hold FLXN as of Q1 2018.

  • Summit Trail Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 18 Flexion Therapeutics, Inc. shares in Q1 2018.
  • Summit Trail Advisors first reported a position in Flexion Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Flexion Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 134 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.